Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | SMYD3 | Q9H7B4 | 16/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL261651 | 0.84 | SMYD3 (0.57) | EPHX2SMYD3GAA | |
| SCHEMBL3389331 | 0.84 | EPHX2 (0.61) | EPHX2SMYD3HTR1ADRD2HTR2A | |
| SCHEMBL4304359 | 0.82 | EPHX2 (0.62) | EPHX2SMYD3HTR1ADRD2HTR2A | |
| SCHEMBL4296460 | 0.80 | EPHX2 (0.57) | EPHX2SMYD3HTR1ADRD2HTR2A | |
| SCHEMBL27805289 | 0.79 | SMYD3 (0.51) | EPHX2SMYD3GAAGRIN2B | |
| SCHEMBL6358832 | 0.79 | GAA (0.48) | EPHX2SMYD3GAAHTR1ADRD2 | |
| SCHEMBL6225349 | 0.78 | EPHX2 (0.57) | EPHX2SMYD3HTR1ADRD2HTR2A | |
| SCHEMBL14815914 | 0.77 | MAOB (0.52) | SMYD3GAA | |
| SCHEMBL2306726 | 0.76 | EPHX2 (0.59) | EPHX2SMYD3HTR1ADRD2HTR2A | |
| SCHEMBL1304506 | 0.76 | EPHX2 (0.59) | EPHX2SMYD3HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| CN-1511151-A | 3-quinoline-2-(1H)-ylideneindolin-2-one derivatives | ֮����ҩ��ʽ���� | 2004-07-07 | — | — | CN | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | EPHX2 4806/4885SMYD3 4119/4885GAA 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.